Navigation Links
USAID awards $5 million to CONRAD

Arlington, VA November 2, 2010 CONRAD, leaders in reproductive health and HIV prevention research, today announced a $5 million award from the US Agency for International Development (USAID). The grant will fund research and development of vaginal rings that are contraceptive and also prevent HIV and STI infections.

USAID provided funding for the CAPRISA 004 trial of tenofovir gel, conducted by the Centre for Programme Research for AIDS in South Africa (CAPRISA), which was the first study to show that a vaginal gel can reduce the risk of HIV and herpes infection in women. CONRAD manufactured and provided the tenofovir gel for the study. Tenofovir gel was found to be 39% effective in reducing a woman's risk of becoming infected with HIV during sex and 51% effective in preventing genital herpes infections in the women participating in the trial. The FDA recently granted Fast Track approval designation for tenofovir gel, pending confirmatory results from the NIH-sponsored Phase IIB study, MTN-003, known as VOICE (Vaginal and Oral Interventions to Control the Epidemic.) CONRAD's pre-clinical and product development team are evaluating products that include combination gels and barrier methods, such as an intravaginal ring impregnated with tenofovir and a contraceptive that is the subject of this grant.

"Thanks to USAID, we have been able to manufacture the first product to reduce women's risk of HIV and herpes," said Henry Gabelnick, Executive Director of CONRAD. "This award will allow us to expedite the evaluation of a dual-protection technology that promises to be a breakthrough in the simultaneous prevention of unplanned pregnancies and HIV infection."

Almost half of all pregnancies worldwide, estimated to be over 100 million annually, are unintended. In sub-Saharan Africa in particular, low contraceptive use rates are reflected by high fertility rates, and thus high infant and maternal mortality rates. This area of the world is also the core of the AIDS epidemic, with 22.4 million people infected with HIV, many of them young women. Poverty, malnutrition, lack of education and gender inequality fuel both unintended pregnancies and HIV transmission; therefore, there is an urgent need to develop dual protection technologies.

"We strongly support research that focuses on women's health in developing countries and a dual-protection product that can prevent unintended pregnancies as well as HIV and other STIs can make an enormous difference," said Dr. Judy Manning with USAID. "CONRAD has been on the forefront of this technology and we are proud to support their work."


Contact: Annette Larkin

Related biology news :

1. USAID grant awarded to improve food security in Africa
2. USDA awards Virginia Tech $3.8 million to stimulate eastern US wine industry
3. NSF awards new projects for plant genome research
4. Landenberger Foundation awards grant to Scripps Florida scientist to study HIV
5. NSF awards $3.75 million grant to New York Plant Genome Consortium for the creation of BigPlant v1.0
6. NSF awards grants for research on coupled natural and human systems
7. NSF awards grants to study effects of ocean acidification
8. USDA awards grant to GSU professor to study childhood obesity dynamics
9. DFG awards 4 young scientists 2010 Bernd Rendel Prize
10. MARC travel awards announced for the ASBMR 2010 annual meeting
11. Knome Awards Human Exome Sequencing and Analysis to Biomedical Researchers
Post Your Comments:
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
(Date:11/25/2015)... Oregon , November 25, 2015 ... Market Research Report is a professional and in-depth ... industry.      (Logo: ) ... overview of the industry including definitions, classifications, applications ... is provided for the international markets including development ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
Breaking Biology Technology: